Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | PTGDR2 | Q9Y5Y4 | 2/20 | 0.39 |
| ▸ | BRD4 | O60885 | 9/20 | 0.39 |
| ▸ | BRD2 | P25440 | 7/20 | 0.39 |
| ▸ | BRD3 | Q15059 | 7/20 | 0.39 |
| ▸ | ABCB1 | P08183 | 3/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL482339 | 0.83 | BRD4 (0.40) | SMN1; SMN2TSHRLMNANPSR1MEN1 | |
| SCHEMBL483265 | 0.77 | TSHR (0.35) | TSHRABCB1 | |
| SCHEMBL483264 | 0.74 | PTGDR2 (0.44) | SMN1; SMN2TSHRLMNANPSR1MEN1 | |
| SCHEMBL482473 | 0.72 | ABCB1 (0.40) | SMN1; SMN2TSHRNPSR1BRD4ABCB1 | |
| SCHEMBL12095224 | 0.71 | BRD4 (0.51) | SMN1; SMN2TSHRLMNAPTGDR2BRD4 | |
| SCHEMBL12095226 | 0.71 | BRD4 (0.51) | SMN1; SMN2TSHRLMNAPTGDR2BRD4 | |
| SCHEMBL12095227 | 0.71 | BRD4 (0.51) | SMN1; SMN2TSHRLMNAPTGDR2BRD4 | |
| SCHEMBL20269863 | 0.70 | BRD4 (0.55) | SMN1; SMN2TSHRPTGDR2BRD4BRD2 | |
| SCHEMBL482835 | 0.69 | SMN1; SMN2 (0.38) | SMN1; SMN2TSHRLMNANPSR1MEN1 | |
| SCHEMBL483269 | 0.67 | NR3C2 (0.41) | LMNAMAPTPTGDR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8604030-B2 | Fused piperidine compound and pharmaceutical containing same | KOWA COMPANY, LTD. (JP) | 2013-12-10 | — | — | US | disclosed |
| US-20120108581-A1 | FUSED PIPERIDINE COMPOUND AND PHARMACEUTICAL CONTAINING SAME | KOWA COMPANY, LTD (JP) | 2012-05-03 | — | — | US | disclosed |
| EP-2412710-A1 | FUSED PIPERIDINE COMPOUND AND PHARMACEUTICAL AGENT COMPRISING SAME | Kowa Company, Ltd. (JP) | 2012-02-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120108581-A1 | FUSED PIPERIDINE COMPOUND AND PHARMACEUTICAL CONTAINING SAME | EPOR, JAK2, HBZ | SMN1; SMN2 1440/4885TSHR 964/4885LMNA 4222/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.